| Page 6 | Aplastic Anemia and MDS International Foundation

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes

Author(s): 
Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Blood Cancer J
Original Publication Date: 
Sep 2017

No abstract available.

Bone Marrow Diseases: 

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Author(s): 
Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A
Primary Author: 
Platzbecker U
Journal Title: 
Lancet Oncol
Original Publication Date: 
Sep 2017

BACKGROUND:

Bone Marrow Diseases: 

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R

Author(s): 
Tefferi A, Lasho TL, Patnaik MM, Saeed L, Mudireddy M, Idossa D, Finke C, Ketterling RP, Pardanani A, Gangat N
Primary Author: 
Tefferi A
Journal Title: 
Am J Hematol
Original Publication Date: 
Sep 2017

A 27-gene panel was used for next-generation sequencing (NGS) in 179 patients (median age 73 years) with primary

Bone Marrow Diseases: 

Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future

Author(s): 
Saad, A and Lamb, LS
Primary Author: 
Saad, A
Journal Title: 
Bone Marrow Transplantation
Original Publication Date: 
Sep 2017

The most common cause of post-transplant mortality in patients with hematological malignancy is relapse, followed by GvHD, infections, organ toxicity and second malignancy. Immune-mediated complications such as GvHD continue to be challenging, yet amenable to control through manipulation of the T-cell compartment of the donor graft with subsequent immunomodulation after transplant. However, risk of both relapse and infection increase concomitantly with T-cell depletion (TCD) strategies that impair immune recovery.

Bone Marrow Diseases: 

Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

Author(s): 
Cogle CR, Reddy SR, Chang E, Papoyan E, Broder MS, McGuire M, Binder G
Primary Author: 
Cogle CR
Journal Title: 
Leuk Res
Original Publication Date: 
Aug 2017

Bone Marrow Diseases: 

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes

Author(s): 
Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Leukemia
Original Publication Date: 
Aug 2017

No absrtact available.